If you have been reading about Angiotensin IV analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Body mass index (BMI) is acceptable for determining obesity for children two years of age and older. It is determined by the ratio of weight to height. The normal range for BMI in children vary with age and sex. While a BMI above the 85th percentile is defined as overweight, a BMI greater than or equal to the 95th percentile is defined as obesity by the Centers for Disease Control and Prevention (CDC). Obesity is further categorized as class 1 obesity with BMI at or above the 95th percentile to 119% of the 95th percentile, class 2 obesity with a BMI 120 to 139% of the 95% percentile and class 3 obesity which is 140% or greater of the 95th percentile. The CDC has published tables for determining this in children. The US Preventive Service Task Force reported that not all children with a high BMI need to lose weight, however. High BMI can identify a possible weight problem, but does not differentiate between fat or lean tissue. Additionally, BMI may mistakenly rule out some children who do have excess adipose tissue. It is therefore beneficial to supplement the reliability of a BMI diagnosis with additional screening tools such as adipose tissue or skin fold measurements.
Free nerve ending A type of unencapsulated nerve ending that detects pain, temperature, and crude touch. These are the most common type of cutaneous receptors. Frontal lobe A region of the cerebral cortex involved in decision-making, planning, motor function, problem-solving, and aspects of personality. Located at the front of each cerebral hemisphere. Frontal eye fields A region in the frontal lobe involved in voluntary eye movements and visual attention. It plays a role in saccadic control and visual tracking. Functional connectivity A measure of how different brain regions interact during rest or tasks, often assessed using fMRI or EEG by examining correlations in activity over time. Functional magnetic resonance imaging (fMRI) A neuroimaging technique that measures brain activity by detecting changes in blood oxygenation (BOLD signal). It is used to study brain function in real time. Fusiform gyrus A brain region located in the temporal and occipital lobes involved in high-level visual processing, including facial recognition and object categorization. Fusiform face area (FFA) A specialized part of the fusiform gyrus that responds selectively to faces. It is often studied in the context of prosopagnosia (face blindness) and visual expertise.
xv. ISBN 978-1-62683-043-1. Retrieved March 22, 2021. Siddiqi, Asif A. (2000). Challenge to Apollo: the Soviet Union and the space race, 1945–1974 (PDF). Washington, D.C.: National Aeronautics and Space Administration, NASA History Div. Retrieved February 10, 2026. Siddiqi, Asif A. (2003). Sputnik and the Soviet Space Challenge. Gainesville: University Press of Florida. ISBN 0-8130-2627-X. Siddiqi, Asif A. (2003). The Soviet Space Race with Apollo. Gainesville: University Press of Florida. ISBN 0-8130-2628-8. Stocker, Jeremy (2004). Britain and Ballistic Missile Defence, 1942–2002. London: Frank Case. pp. 12–24. ISBN 0-7146-5696-8. Swenson, Loyd S. Jr.; Grimwood, James M.; Alexander, Charles C. (1966). This New Ocean: A History of Project Mercury. NASA. ISBN 1-934941-87-5. Retrieved January 8, 2023. Turnhill, Reginald (2004). The Moonlandings: An Eyewitness Account. New York: Cambridge University Press. ISBN 0-521-81595-9. Pervushin, Anton (2011). 108 minutes which changed the world (in Russian). Эксмо. ISBN 978-5-699-48001-2.
Pakistan's untapped coal reserves have been estimated as the fifth largest in the world and equivalent to about 400 billion barrels of oil, exceeding the combined oil reserves of Saudi Arabia and Iran. Daniel Fitzgerald Runde wrote in Forbes in 2016 that Pakistan "could be the 'Saudi Arabia of Coal'." The Reko Diq Mine has one of the world's largest undeveloped copper deposits, with an estimated 15 million tonnes in reserves, and is expected to become the world's fifth largest copper mine upon completion; a feasibility study also estimates that it could produce approximately 17.9 million ounces of gold over its projected 37-year mine life, with total copper and gold reserves valued at over $60 billion at prevailing prices.
Sources: en.wikipedia.org
== Occurrence in foods and beverages == 2,5-Diketopiperazines are often formed during cooking from naturally occurring oligopeptides in foodstuffs. They have been detected in foods such as stewed beef, beer, barley bread, Awamori, dark chocolate, coffee and Comté cheese. 2,5-diketopiperazines have been shown to be important sensory compounds that help to influence the taste of a food product. The proline derived 2,5-diketopiperazines are the most abundant and structurally diverse class of 2,5-diketopiperazines found in food. The valine derivative cyclo(L-Val-L-Pro) at a concentration of 1742 ppm, was identified as the most important bitter 2,5-diketopiperazine contributing to the bitter taste of roasted cocoa. It has also been found as one of the major 2,5-diketopiperazines in autolyzed yeast extract and stewed beef and is also present in chicken essence and coffee. It has also been isolated from a variety of marine microorganisms and has been identified as an active LasI quorum-sensing signal molecule important for the plant growth promotion by Pseudomonas aeruginosa. The most studied of all the simple 2,5-diketopiperazines is the histidyl-proline 2,5-diketopiperazine cyclo(L-His-L-Pro) which is found in a variety of foods, with particularly high concentrations in fish and fish products. It is well absorbed orally, and crosses the blood–brain barrier via a non-saturable mechanism.
These complexes are often laid out in a similar fashion, and they can contain many different modules to perform a diverse set of chemical manipulations on the developing product. These peptides are often cyclic and can have highly complex cyclic structures, although linear nonribosomal peptides are also common. Since the system is closely related to the machinery for building fatty acids and polyketides, hybrid compounds are often found. The presence of oxazoles or thiazoles often indicates that the compound was synthesized in this fashion. Peptones are derived from animal milk or meat digested by proteolysis. In addition to containing small peptides, the resulting material includes fats, metals, salts, vitamins, and many other biological compounds. Peptones are used in nutrient media for growing bacteria and fungi. Peptide fragments refer to fragments of proteins that are used to identify or quantify the source protein. Often these are the products of enzymatic degradation performed in the laboratory on a controlled sample, but can also be forensic or paleontological samples that have been degraded by natural effects.
== Treatment == Although feline cutaneous asthenia is not curable, there are treatment and management options for the disease. Affected animals must be kept away from others, and sharp corners on tables and other furniture must be padded. Cats should have their claws regularly trimmed so that they cannot injure themselves while scratching, and it is often advised that males be neutered, both because of the heritability of the disease and because there is a chance of injury during mating. If something causes the skin to tear, it should be sutured if possible, and the wound should be treated with antibiotics as needed. Vitamin C is also given to cats in controlled doses, to assist with the translation of collagen. Given proper care, cats with feline cutaneous asthenia can live long lives, although the prognosis is not as positive if joint hypermobility is present.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.